Preferred Label : Zanzalintinib;
NCIt synonyms : 1,1-Cyclopropanedicarboxamide, N-(4-fluorophenyl)-N'-(4-((7-methoxy-6-((methylamino)carbonyl)-4-quinolinyl)oxy)phenyl)-; Multi-kinase Inhibitor XL092; N-(4-Fluorophenyl)-N'-(4-((7-methoxy-6- (methylcarbamoyl)quinolin-4- yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide;
NCIt definition : An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) hepatocyte
growth factor receptor (c-Met; HGFR), vascular endothelial growth factor receptor
type 2 (VEGFR2), AXL and MER, with potential anti-angiogenesis and antineoplastic
activities. Upon oral administration, zanzalintinib targets and binds to c-Met, VEGFR2,
AXL and MER, and prevents their RTK activity. This blocks c-Met/VEGFR2/AXL/MER-mediated
signal transduction pathways, and inhibits the proliferation and migration of c-Met-,
VEGFR2-, AXL- and MER-overexpressing tumor cells. c-Met, overexpressed in many tumor
cell types, plays a critical role in tumor formation, proliferation, invasion and
metastasis, and contributes to tumor resistance. VEGFR2, overexpressed in certain
tumor types, plays an essential role in angiogenesis and the proliferation, survival,
migration and differentiation of endothelial cells. AXL and MER, both members of the
TAM (Tyro3, Axl and Mer) family of RTKs, are overexpressed by many tumor cell types.
They play key roles in tumor cell proliferation, survival, invasion, angiogenesis
and metastasis, and their expression is associated with enhanced immunosuppression,
drug resistance and poor prognosis.;
UNII : KC2JC2ZA04;
CAS number : 2367004-54-2;
Molecule name : XL-092; XL 092;
NCI Metathesaurus CUI : CL970131;
Origin ID : C161598;
UMLS CUI : C5706574;
Semantic type(s)
- concept_is_in_subset
- has_salt_form
- has_target
- is_free_acid_or_base_form_of
